Analysts Set Insmed Incorporated (NASDAQ:INSM) Target Price at $94.00

Insmed Incorporated (NASDAQ:INSM) has been given a consensus recommendation of “Buy” by the sixteen brokerages that are presently covering the firm, MarketBeat Ratings reports. Sixteen research analysts have rated the stock with a buy recommendation. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $94.00.

INSM has been the subject of a number of research analyst reports. Stifel Nicolaus cut their price objective on shares of Insmed from $97.00 to $96.00 and set a “buy” rating for the company in a report on Friday, February 21st. Guggenheim reiterated a “buy” rating and issued a $101.00 price target on shares of Insmed in a report on Tuesday, February 25th. Truist Financial increased their price objective on shares of Insmed from $105.00 to $108.00 and gave the company a “buy” rating in a report on Friday, February 21st. UBS Group lifted their target price on Insmed from $105.00 to $110.00 and gave the stock a “buy” rating in a report on Thursday, March 6th. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $100.00 price target on shares of Insmed in a research note on Wednesday, March 19th.

Insider Buying and Selling

In related news, CFO Sara Bonstein sold 3,470 shares of the stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $65.70, for a total transaction of $227,979.00. Following the completion of the transaction, the chief financial officer now directly owns 114,736 shares of the company’s stock, valued at $7,538,155.20. This represents a 2.94 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CEO William Lewis sold 18,750 shares of Insmed stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $77.03, for a total value of $1,444,312.50. Following the completion of the sale, the chief executive officer now owns 334,186 shares in the company, valued at approximately $25,742,347.58. This trade represents a 5.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 550,957 shares of company stock worth $42,992,528 over the last 90 days. 4.60% of the stock is owned by insiders.

Institutional Investors Weigh In On Insmed

A number of institutional investors and hedge funds have recently modified their holdings of INSM. National Bank of Canada FI grew its position in shares of Insmed by 9.7% in the fourth quarter. National Bank of Canada FI now owns 1,668 shares of the biopharmaceutical company’s stock valued at $115,000 after purchasing an additional 147 shares during the last quarter. Abel Hall LLC increased its holdings in shares of Insmed by 4.7% during the 4th quarter. Abel Hall LLC now owns 3,333 shares of the biopharmaceutical company’s stock worth $230,000 after buying an additional 151 shares during the last quarter. Snowden Capital Advisors LLC increased its stake in Insmed by 2.5% during the fourth quarter. Snowden Capital Advisors LLC now owns 6,602 shares of the biopharmaceutical company’s stock worth $456,000 after acquiring an additional 158 shares during the last quarter. Commerce Bank raised its holdings in Insmed by 2.4% in the third quarter. Commerce Bank now owns 6,833 shares of the biopharmaceutical company’s stock valued at $499,000 after buying an additional 163 shares during the period. Finally, Steward Partners Investment Advisory LLC raised its stake in shares of Insmed by 65.2% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company’s stock valued at $29,000 after acquiring an additional 163 shares during the period.

Insmed Stock Down 1.1 %

Insmed stock opened at $78.54 on Friday. Insmed has a 12 month low of $21.92 and a 12 month high of $84.91. The stock has a fifty day simple moving average of $77.84 and a two-hundred day simple moving average of $73.89. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03. The firm has a market cap of $14.22 billion, a price-to-earnings ratio of -14.05 and a beta of 1.28.

Insmed (NASDAQ:INSM) last released its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, missing the consensus estimate of ($1.17) by ($0.15). Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. The firm had revenue of $104.44 million for the quarter, compared to the consensus estimate of $102.31 million. Equities analysts predict that Insmed will post -4.56 EPS for the current fiscal year.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.